Related Experiment Video
Updated: Sep 19, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Respiratory Syncytial Virus Disease Burden and Evidence Gaps in Australia Before Immunisation Introduction: A
Chisato Imai-Boulter1,2,3, Jean Li-Kim-Moy1,2, Clayton Chiu1,2
1National Centre for Immunisation Research and Surveillance, Sydney, New South Wales, Australia.
Abstract:
This study evaluated Australia's national respiratory syncytial virus (RSV) burden and highlighted key data gaps. Hospitalisations (2016-2019) peaked in infants aged < 3 months (4014/100,000) and adults aged ≥ 65 years (122/100,000), nearly doubling over the period. Unspecified causes comprised ≈55% of bronchiolitis hospitalisations in children aged < 24 months. Laboratory notifications (2023) peaked at 6-11 months (7778/100,000). Real-time data integration addressing case-ascertainment and diagnostic testing frequency is essential for accurate burden estimates and future immunisation strategies.
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Vaccinations
Coronavirus
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Poliomyelitis

